Article
Serum platelet-activating factor acetylhydrolase activity: A novel potential inflammatory marker in type 1 diabetes
Registro en:
GOMES, Marilia de Brito et al. Serum platelet-activating factor acetylhydrolase activity: A novel potential inflammatory marker in type 1 diabetes. Prostaglandins & other Lipid Mediators, v. 87, p. 42-46, July 2008.
1098-8823
10.1016/j.prostaglandins.2008.07.001
Autor
Gomes, Marilia de Brito
Cobas, Roberta Arnold
Nunes, Edson
Nery, Michele
Faria Neto, Hugo Caire C.
Tibiriçá, Eduardo
Resumen
Plasma activity of the platelet-activating factor acetylhydrolase (PAF-AH) plays an important role in
inflammation and atherosclerotic process in chronic diseases. We aimed to evaluate the levels of PAFAH
activity and their association with the metabolic profile and chronic complications in patients
with type 1 diabetes. The study included 118 outpatients (54 males) aged 27.1±11.3 years with disease
duration of 12.3±8.5 years with (n = 38) or without (n = 80) diabetes complications and 96 control
subjects (48 males) matched for age, gender, body mass index and smoking habits. The serum levels
of PAF-AH activity were higher in patients either with or without chronic complications (16±5.3 and
14±5.4 nmol/(min mL), respectively) than in controls (13±5.1 nmol/(min mL), P = 0.02). In the total population,
PAF-AH activity was correlated with age, HDL-cholesterol, total cholesterol and LDL-cholesterol.
In patients, PAF-AH activity was correlated with age, HbA1c, uric acid, HDL-cholesterol, cholesterol,
LDL-cholesterol, cholesterol/HDL-cholesterol ratio and the LDL-cholesterol/HDL-cholesterol ratio. It is
concluded that PAF-AH plasma activity could be a novel candidate for low-grade inflammatory marker in
patients with type 1 diabetes. 2022-01-01